A first-in-human phase 1/1b study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors

被引：0
|
作者：
Schwartz, G. [1 ]
Adkins, D. [2 ]
Heist, R. [3 ]
Werner, T. [4 ]
Abbott, M. [1 ]
Barber, S. [2 ]
Slusarz, K. [3 ]
Agarwal, N. [4 ]
Neuteboom, S. [5 ]
Faltaos, D. [5 ]
Chen, I. [5 ]
Christensen, J. [6 ]
Chao, R. [5 ]
Bauer, T. [7 ]
机构：
[1] Columbia Univ, Div Hematol & Oncol, Med Ctr, New York, NY USA
[2] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[3] Massachusetts Gen Hosp, Ctr Canc, Hematol Oncol, Boston, MA USA
[4] Huntsman Canc Inst, Div Oncol, Salt Lake City, UT USA
[5] Mirati Therapeut, Clin Sci, San Diego, CA USA
[6] Mirati Therapeut, Discovery & Translat Sci, San Diego, CA USA
[7] Tennessee Oncol PLLC, Oncol, Sarah Cannon Res Inst, Nashville, TN USA
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30233-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
370
引用
收藏
页码：S78 / S78
页数：1
相关论文
共 50 条
  • [31] First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors
    Patricia M. LoRusso
    Priscila H. Goncalves
    Lindsay Casetta
    Judith A. Carter
    Kevin Litwiler
    Dale Roseberry
    Selena Rush
    Jennifer Schreiber
    Heidi M. Simmons
    Mieke Ptaszynski
    Edward A. Sausville
    Investigational New Drugs, 2015, 33 : 440 - 449
  • [32] First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors
    LoRusso, Patricia M.
    Goncalves, Priscila H.
    Casetta, Lindsay
    Carter, Judith A.
    Litwiler, Kevin
    Roseberry, Dale
    Rush, Selena
    Schreiber, Jennifer
    Simmons, Heidi M.
    Ptaszynski, Mieke
    Sausville, Edward A.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (02) : 440 - 449
  • [33] First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors.
    Falchook, Gerald Steven
    Liang, Yan
    Harvey, R. Donald
    Fu, Siqing
    Weitao, Yao
    Qin, Yan-Ru
    Zhang, Xiaojing
    Henry, Jason Timothy
    Zou, Qingping
    Shan, Boyao
    Liang, Pan
    Wang, Chen
    Li, Wenjia
    Pamuklar, Zehra Nurgul
    Pei, Yi
    Chang, Zhiwei
    Wang, Jiaqiang
    Piha-Paul, Sarina A.
    Bhave, Manali A.
    Yin, Yongmei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] AC220, A POTENT, SELECTIVE, SECOND GENERATION FLT3 RECEPTOR TYROSINE KINASE (RTK) INHIBITOR, IN A FIRST-IN-HUMAN PHASE 1 AML STUDY
    Trikha, M.
    Cortes, J.
    Foran, J.
    Ghirdaladze, D.
    Devetten, M.
    Zodelava, M.
    Holman, P.
    Levis, M.
    Kantarjian, H.
    Borthakur, G.
    James, J.
    Armstrong, R.
    Zarrinkar, P.
    Padre, N.
    Wierenga, W.
    Corringham, R.
    ANNALS OF ONCOLOGY, 2010, 21 : 22 - 22
  • [35] Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumors
    Moore, Kathleen N.
    Jones, Suzanne Fields
    Kurkjian, Carla
    Arkenau, Hendrik-Tobias
    Infante, Jeffrey R.
    Pant, Shubham
    Burris, Howard A.
    McMeekin, D. Scott
    Gibbons, Jay
    Harrow, Kimberly
    Liang, Chris
    Ramsey, Sara
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] IPI-549-01-A Phase 1/1b, first-in-human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors
    Tolcher, Anthony
    Hong, David
    Sullivan, Ryan
    Mier, James
    Shapiro, Geoffrey
    Chmielowski, Bartosz
    Ribas, Antoni
    Postow, Michael
    Pearlberg, Joseph
    Brail, Les
    Lee, Lucy
    Ullmann, Claudio A. Dansky
    Wolchok, Jedd D.
    CANCER RESEARCH, 2017, 77
  • [37] First-in-human phase 1 study of DS-1062a in patients (pts) with advanced solid tumors (AST).
    Sands, Jacob M.
    Shimizu, Toshio
    Garon, Edward B.
    Greenberg, Jonathan
    Heist, Rebecca Suk
    Kobayashi, Fumiaki
    Noguchi, Yutaka
    Okajima, Daisuke
    Spira, Alexander I.
    Yamamoto, Noboru
    Yamashita, Tomonari
    Lisberg, Aaron Elliott
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] AC220, A POTENT, SELECTIVE, SECOND GENERATION FLT3 RECEPTOR TYROSINE KINASE (RTK) INHIBITOR, IN A FIRST-IN-HUMAN PHASE 1 AML STUDY
    Trikha, M.
    Cortes, J.
    Foran, J.
    Ghirdaladze, D.
    DeVetten, M.
    Zodelava, M.
    Holman, P.
    Levis, M.
    Kantarjian, H.
    Borthakur, G.
    James, J.
    Armstrong, R.
    Zarrinkar, P.
    Padre, N.
    Wierenga, W.
    Corringham, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 460 - 461
  • [39] A phase 1b study to assess the safety of PLX3397, a CSF-1 receptor inhibitor, and paclitaxel in patients with advanced solid tumors
    Sharma, Neelesh
    Wesolowski, Robert
    Reebel, Laura
    Rodal, Mary Beth
    Peck, Alexandra
    West, Brian
    Karlin, David Alan
    Dowlati, Afshln
    Le, Mal H.
    Coussens, Lisa M.
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors
    Drilon, A.
    Marwan, F.
    Fu, S.
    Patel, M. R.
    Olszanski, A. J.
    Lockhart, A. C.
    Liu, S. V.
    Bazhenova, L.
    Seery, T.
    Nikolinakos, P.
    Patel, R.
    Oliver, J. W.
    Multani, P. S.
    Wang, D.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S143 - S143
12345